Generate Biomedicines, Inc. (GENB) company profile
GENBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$9.84−0.65 (-6.20%)
Close on Nov 17, 2026Market cap $1.26BP/E –Yield –
About Generate Biomedicines
Pharmaceutical Preparations, SIC 2834
Generate Biomedicines, Inc. is listed on Nasdaq under the ticker GENB, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- Generate Biomedicines, Inc.
- Headquarters
- Somerville, MA
- Address
- 101 South Street, Suite 900 02143
- Phone
- (888) 469-0055
- Website
- generatebiomedicines.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- GENB
- Exchange
- Nasdaq
- IPO date
- Feb 27, 2026
- Shares outstanding
- 128M, Jul 29, 2026
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 2100782
- CUSIP
- 370920100
- ISIN
- US3709201004
- FIGI
- BBG00X9D0NZ0
- Share class FIGI
- BBG00X9D0P03
- EIN
- 83-1630228
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Michael Nally | Chief Executive Officer, Director | 2,889,154 |
| Gevorg Grigoryan | Chief Technology Officer | 659,973 |
| Beth Grous | Chief People Officer | 300 |
| Laurie Anne Lee | Chief Medical Officer | – |
| Jason Silvers | President & CFO | 1,500 |
| Sean Martin | Chief Legal Officer & GC | – |
| Aarif Khakoo | Chief Scientific Officer | – |
| Frances Arnold | Director | 452,535 |
| Paul Gray Parker | Director | – |
| Nancy A. Simonian | Director | – |
| Jane L. Mendillo | Director | 1,500 |
| Marsha Fanucci | Director | – |
| Rupert Vessey | Director | – |
| Noubar Afeyan | Director | – |
| Stephane Bancel | Director | 1,184,989 |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Feb 27, 2026
- Offer price
- $16.00
- Securities offered
- 25,000,000
- Gross proceeds
- $400.00M
- Exchange
- Nasdaq
- First trading day
- Feb 27, 2026
- First-day close
- $12.65-20.9%
- Lock-up ends (est.)
- Aug 26, 2026
“The initial public offering price per share is $16.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 27, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 24, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?